Department of Hematology and Oncology, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, International Cancer Center, Shenzhen University General Hospital, Shenzhen University Health Science Center, Shenzhen University, Xueyuan AVE 1098, Nanshan District, Shenzhen 518000, Guangdong, China.
Central Laboratory, Shenzhen University General Hospital, Xueyuan AVE 1098, Nanshan District, Shenzhen 518000, Guangdong, China.
Curr Oncol. 2021 Feb 26;28(2):1077-1093. doi: 10.3390/curroncol28020105.
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clinical practice, but their efficacy is not sufficient to suppress tumor development mainly because of lacking specificity. To this end, the engineering of NK cells with T cell receptor along with CD3 subunits (TCR-NK) has been developed to increase the reactivity and recognition specificity of NK cells toward tumor cells. Here, we review recent advances in redirecting NK cells for cancer immunotherapy and discuss the major challenges and future explorations for their clinical applications.
自然杀伤 (NK) 细胞由于能够在无需预先致敏或人类白细胞抗原匹配的情况下溶解肿瘤靶标，因此可广泛应用于癌症免疫疗法。已经在临床实践中尝试了几种基于 NK 的治疗方法，但由于缺乏特异性，其疗效不足以抑制肿瘤的发展。为此，人们开发了带有 T 细胞受体和 CD3 亚基的 NK 细胞（TCR-NK），以提高 NK 细胞对肿瘤细胞的反应性和识别特异性。在这里，我们综述了用于癌症免疫疗法的 NK 细胞重定向的最新进展，并讨论了其临床应用的主要挑战和未来探索方向。
